Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth"

Eur J Dermatol. 2013 Apr 1;23(2):212-7. doi: 10.1684/ejd.2013.1988.

Abstract

Background: Psoriasis vulgaris is a common disease that follows a chronic course. So far, few studies have addressed outcome methods which evaluate the benefits of drugs and medical devices by measuring patient preferences.

Objective: Assessment of patients' outcomes using the "Patient benefit index" (PBI), a validated goal attainment scaling tool, in the treatment of psoriasis. Data were obtained within an epidemiological study in 2,009 patients with psoriasis vulgaris and/or psoriatic arthritis.

Methods: Cross-sectional study in 133 nationwide German dermatological practices and hospital departments. The following were recorded a) in the doctors' questionnaire--previous treatments and diseases, clinical characteristics and psoriasis area and severity index (PASI), b) in the patients' questionnaire--quality of life (LQ), patient-relevant therapeutic benefits and satisfaction with care.

Results: On average, patients achieved a total PBI of 2.5±1.1. 86.7% of patients showed a more than minimum benefit (PBI>1). Patients treated with biologicals had a higher benefit (mean PBI 3.0) than patients in other groups (e.g. PBI 2.6 in systemics).

Conclusion: PBI values indicate that systemic agents and biologics are of high therapeutic benefit to the vast majority of patients. The development of the PBI has enabled a decisive step to be taken in the area of scientifically-based outcome assessments.

Keywords: Patient Benefit Index; PsoHealth; care; outcome research; patient benefit; psoriasis; quality of life.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biological Therapy*
  • Cross-Sectional Studies
  • Dermatologic Agents / therapeutic use
  • Female
  • Germany
  • Humans
  • Male
  • Middle Aged
  • PUVA Therapy*
  • Patient Satisfaction*
  • Psoriasis / drug therapy*
  • Quality of Life
  • Severity of Illness Index
  • Surveys and Questionnaires
  • Treatment Outcome
  • Young Adult

Substances

  • Dermatologic Agents